Results 41 to 50 of about 67,212 (289)
Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study [PDF]
, 2018 Introduction: The management of bisphosphonate-related osteonecrosis of the jaw (BRONJ), with no evidence-based guidelines, remains controversial. We aimed to evaluate the efficiency of a conservative surgical treatment combining Er,Cr:YSGG laser and ...
Albanese, Antonino +10 more
core +1 more source
Annals of Geriatric Medicine and Research, 2016 Background: Osteoporosis is commonly treated with bisphosphonates. These drugs promote osteoclast apoptosis, which suppresses bone resorption. However, the probability of side effects increases with long-term use of bisphosphonates.
Seo Young Lee +7 more
doaj +1 more source
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis [PDF]
, 2006 BACKGROUND: Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture. METHODS: We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration ...
Ale Algra +14 more
core +4 more sources
FEBS Letters, EarlyView.This study reveals a unique active site enriched in methionine residues and demonstrates that these residues play a critical role by stabilizing carbocation intermediates through novel sulfur–cation interactions. Structure‐guided mutagenesis further revealed variants with significantly altered product profiles, enhancing pseudopterosin formation. These
Marion Ringel +13 more
wiley +1 more source
Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. [PDF]
, 2011 The relaxed complex scheme, a virtual-screening methodology that accounts for protein receptor flexibility, was used to identify a low-micromolar, non-bisphosphonate inhibitor of farnesyl diphosphate synthase.
Cao, Rong +7 more
core +2 more sources
Arthritis Care &Research, EarlyView.Objective We evaluated the role of 25‐hydroxyvitamin D (25[OH]D), prednisone, and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25(OH)D levels and other potential risk factors and BMD measures (spine T scores) and osteoporosis (defined as a T ...
Nima Madanchi +4 more
wiley +1 more source
Enhanced osteogenic differentiation in zoledronate-treated osteoporotic patients [PDF]
, 2017 Bisphosphonates are well known inhibitors of osteoclast activity and thus may be employed to influence osteoblast activity. The present study was designed to evaluate the in vivo effects of zoledronic acid (ZA) on the proliferation and osteoblastic ...
Carbonare, Luca Dalle +7 more
core +6 more sources
Association of oral bisphosphonates with cardioembolic ischemic stroke: a nested case-control study
Frontiers in Pharmacology, 2023 Background: Bisphosphonates have been reported to increase the risk of atrial fibrillation. Therefore, it is conceivable that they may increase the risk of cardioembolic ischemic stroke (IS).
Sara Rodríguez-Martín +11 more
doaj +1 more source
Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011) [PDF]
, 2011 Every 2 years, the International Consensus Conference on the Treatment of Primary Breast Cancer takes place in St. Gallen. Given that the concept of the St.
Beckmann, Matthias W. +27 more
core +1 more source
Advanced Functional Materials, EarlyView.We report a versatile nanoclay gel carrier platform that enhances the osteogenic efficacy of demineralized bone matrix (DBM) by integrating nanoclay‐based self‐assembly with cell‐derived exosome mimetics loaded with noggin‐targeting miR‐200c. This design amplifies BMP signaling, thereby promoting DBM‐mediated osteogenesis and offering a promising ...
Changlu Xu +7 more
wiley +1 more source